

Development of first-in-class small molecule inhibitor targeting novel transcriptional regulator for cancer immunotherapy

SAMJIN PHARM.CO.,LTD.

The logo for SAMJIN, featuring the word "SAMJIN" in white capital letters inside a green oval.

ONCOLOGY	Lead
Product Type	Small molecules
Indication	ICI-resistant solid tumor (melanoma, colon cancer and ovarian cancer)
Target	Novel transcriptional regulator function in both cancer and immune cells
MoA(Mechanism of Action)	By simultaneously targeting T cells and cancer cells, SJN309 increases T cell activity and pro-inflammatory cytokines and inhibits cancer growth and immune evasion.
Competitiveness	A first-in-class small molecule inhibitor targeting novel transcriptional regulator for ICI-resistant cancer treatment
Development Stage	Lead
Route of Administration	PO